Brief: Transgene Expects Significant Clinical Results In 2022

Transgene SA

16/03/2022 16:58

March 16 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE CONFIRMS THE POTENTIAL OF ITS TWO INNOVATIVE
PLATFORMS
AND EXPECTS SIGNIFICANT CLINICAL RESULTS IN 2022
    * TG4050 (MYVAC®): FIRST POSITIVE RESULTS FROM TWO PHASE I
TRIALS.
ADDITIONAL DATA TO BE PRESENTED AT AACR 2022 IN APRIL
    * TG4001: FIRST PATIENT ENROLLED IN PHASE II STUDY IN JUNE
2021.
ACTIVE PATIENT RECRUITMENT IN EUROPE AND TRIAL INITIATION IN US.
INTERIM ANALYSIS EXPECTED IN Q4 2022
    * BT-001 (INVIR.IO™): IND APPROVAL FOR PHASE I/IIA TRIAL IN
US,
ONGOING ENROLLMENT IN EUROPE. NEXT CLINICAL UPDATE IN Q2 2022
    * TG6002: CLINICAL PROOF-OF-CONCEPT OF INTRAVENOUS
ADMINISTRATION
OF AN ONCOLYTIC VIRUS PRESENTED AT MAJOR CONGRESSES IN 2021. END
OF PHASE I EXPECTED IN MID-2022
    * TRANSGENE SA - ASTRAZENECA COLLABORATION (INVIR.IO™):
FIRST
OPTION LICENSE FOR AN ONCOLYTIC VIRUS EXERCISED IN 2021.
RESEARCH AND DEVELOPMENT COLLABORATION TO DEVELOP ADDITIONAL
CANDIDATES ONGOING
    * TRANSGENE SA - EUR 49.6 MILLION CASH AVAILABLE AT YEAR-END
2021
PROVIDING FINANCIAL VISIBILITY UNTIL END OF 2023

Source text for Eikon:  ID:nBw10HDwta 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))